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Porcine red blood cells express a 
polyagglutinable red blood cell phenotype
 
The shortage of human blood and organs has led to
increased interest in animal substitutes. In both trans-
plantation and transfusion, the greatest roadblock to the
use of animal tissues is the expression of xenoantigens. A









4GlcNAc-R), a cross-reactive, B-like antigen expressed on
red blood cells (RBCs) and other tissues that is recognized










experience with porcine RBCs (pRBCs) from genetically


















Gal– animals showed a marked decrease in
hemolysis and immunoglobulin G and immunoglobulin
M binding after incubation in human serum. Although





occurred, suggesting the presence of other xenoantigens.
This was confirmed by in vivo studies in baboons, which









Gal– and wild-type pRBCs. It was hypothesized
that pRBCs were removed by hepatic macrophages, pos-
sibly via an endogenous lectin on Kupffer cells.
We would like to share our serologic results using
lectins of defined specificity, which showed that pRBCs
express a polyagglutinable phenotype that is independent
of linear B expression. Several years ago, one of us (J.L.S.)
routinely typed pigs for the transplant surgery research
program. Washed pRBCs were forward typed as group A
or “O” with commercial murine monoclonal antibodies
(MoAbs) by standard-tube agglutination (Table 1). No
animal typed as group B. The presence of linear B was














As shown in Table 1, regardless of ABO type,





, PNA). Only three animals were PNA-




was an autosomal dominant phenotype. In addition to














 (SHA). Most animals were also positive with









 (LBA). Titration and adsorption studies suggested
 















Results by pig ABO type






















































































1-3GalNAc T 264 261 (99) 175 (99) 71 (98)
Strong positive 256 (97) 173 (97) 68 (94)
Weak positive 5 (2) 3 (2) 3 (4)
















 (BPA)¶ Gal/GalNAc T, lactose 29 26 (90) NA NA
* Data are reported as number (%).
† Porcine RBCs were forward typed with anti-A and anti-B murine MoAbs according to manufacturer’s instructions for human RBCs. RBCs that 




 271 animals). Note that no pRBCs were agglutinated 
by anti-H lectin, UEA-1.






















-0) based on the strength of agglutination 
with the lectins DBA and PNA.
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that DBA recognized a unique, cross-reactive A-like anti-





defined in older literature. There was no correlation










 that pRBCs may express additional carbohy-
drate epitopes, capable of binding naturally occurring
antibodies and/or endogenous lectins, to affect pRBC
hemolysis and removal. A similar conclusion was reported




 who observed strong hemag-
glutination of pRBCs with human serum depleted of anti-





glycolipid antigens in pigs and sheep were recently iden-
tified as potential novel xenoantigens, as evidenced by
their reactivity with AB human serum that had been









Our results show that pRBCs share features with
many polyagglutinable RBC phenotypes (Table 2). A
known senescent antigen on human RBCs, T-antigen is





 Shortened RBC survival and hemolysis are also





the Tk antigen has been implicated in the short survival of




C. Cold storage is associated with the




















In summary, these results emphasize the problems
facing xenotransplantation. Genetically engineered ani-
mals, which lack linear B antigen and/or Forssman anti-
gen expression, may still be quite antigenic owing to
species-specific differences in the regulation and expres-
sion of other carbohydrate antigens. More research into
the differentiation and regulation of cell surface glycosy-
lation in humans and animals is needed.
 
Jane L. Swanson, MS
 
Emerita Research Fellow
Department of Laboratory Medicine and Pathology
University of Minnesota Hospital and Clinic
Minneapolis, MN 55455
 
Laura Cooling, MD, MS
 
Department of Pathology
University of Michigan Hospitals
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The above letter was sent to Rouhani et al.: Drs Dor,
Rouhani, and Cooper offered the following reply.
 








 in which they
provide evidence that porcine red blood cells (pRBCs)









Gal; linear B) expression.





Gal gene-knockout pigs. As they provide evi-


















Gal gene may alter the glycosylation pattern on




resulting in exposure of neoantigens, which could lead to
destruction of these pig cells by antibodies or other con-
stituents of the host immune response. One potential par-





epitopes with another oligosaccharide (through trans-
genic expression of a human gene) that would not be
bound by human antibodies, for example, that for the









Serologic reactivity with lectins* and AB human serum
Human serum DBA PNA SBA SSA SHA GS1
pRBCs
 



















































* See Table 1 for lectin names and specificity.
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Travel-related hepatitis A detected by 
hepatitis A virus RNA donor screening
 





 describing molecular and serologic tracing of
transfusion-transmitted hepatitis A virus (HAV) between
a blood donor and recipient. We describe the application
of reverse transcription–polymerase chain reaction (RT-
PCR) and phylogenetic analysis to tracing acute
hepatitis A infections in two blood donors to a common
source of HAV infection during their vacations in Egypt.
Within a 3-week period, two blood donations from
different regions of Germany (Donor A, July 22, 2004; and
Donor B, August 12, 2004) tested positive by HAV PCR dur-
ing routine processing at the Red Cross Blood Transfusion
Service West. Both donors were asymptomatic and neither
had been vaccinated against hepatitis A. Both had
recently returned from holiday trips to Hurghada, Egypt,
where they stayed in different, but neighboring, Red Sea
beach hotels. They were not deferred as blood donors,
because Hurghada is not a known risk area.
Routinely, all blood donated at the Red Cross Blood
Transfusion Service West is tested by PCR for HCV, human
immunodeficiency virus-1 (mandatory by German Guide-
lines), hepatitis B virus, parvovirus B19 DNA, and HAV





 PCR screening of plasma is conducted
using 96-sample minipools at the Laboratory of the Red
Cross Blood Transfusion Service Baden-Wuerttemberg-
Hessen by real-time PCR. PCR-positive minipools are
traced back by chessboard-pooling and confirmed by
single-donation PCR.
Additional testing for these two donors included
quantitative PCR performed by one-tube RT-PCR (RealArt
HAV LC RT-PCR kits, artus GmbH, Hamburg, Germany).
Full-length RNA was reverse-transcribed and subse-
quently amplified and sequenced (DNA Cloning Service,
Hamburg, Germany). Sequence data analysis was per-
formed by CLUSTAL W algorithm. Quantification of HAV
with the donors’ fresh frozen plasma revealed titers of
2.5 EE2 IU per mL (Donor A) and 5.3 EE3 IU per mL
(Donor B). The closest sequence match to GenBank was





 Sequence analysis of both strains isolated from the
plasma units revealed 100 percent homology, confirming
a common source of their infections. Sequence alignment
to known strains of HAV matched genotype 1B for both
donations (Fig. 1). Typically, genotype 1A predominates in
Germany.
The donors were informed about their test results,
asked for follow-up blood samples, and interviewed by
telephone to investigate the possible sources for their HAV
infections. No follow-up sample was available from
Donor A. His family doctor reported that he was hospital-
ized on August 5, 2004, because of jaundice, abdominal
pain, fatigue, and loss of appetite. Hepatitis A was diag-
nosed and confirmed by the presence of anti-HAV immu-
noglobulin M (IgM) and immunoglobulin G (IgG). His
apartase aminotransferase level was 11,120 U per L and
his alanine aminotransferase level was 5,664 U per mL. He
recovered in 2 weeks. A follow-up sample from Donor B
from August 19, 2004, was positive for both anti-HAV IgM
and IgG and HAV PCR. He was asymptomatic, but 9 days
later, he developed fever, pain in the upper abdomen,
arthralgies, and one episode of dark urine. This illness
lasted 2 days. The specific source of their infections has
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 Four weeks after the donors
departed, however, one of the hotels was identified as





This experience alerts us that there is a substantial
risk for hepatitis A among nonvaccinated tourists not only
in known regions of known high risk for
hepatitis A, but also in certain areas
where the risk has not been recognized.
When blood is donated shortly after a
stay in an HAV high-risk region, either
testing donations by HAV NAT or a tem-
porary deferral of donors (when com-
mon source outbreaks are recognized)
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Phylogenetic analysis of the two HAV strains isolated of the plasma unit 
(Donors A and B). Numbers at the branches indicate bootstrap percentage after 1000 
replications of bootstrap sampling. The bar indicates genetic distance.
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Lack of correlation between hepatitis B 
surface antigen and hepatitis B virus DNA 






 report a lack of correlation between
hepatitis B surface antigen (HBsAg) and hepatitis B virus
(HBV) DNA levels in chronic carriers of HBV. We would
like to confirm this conclusion with data obtained in
blood donors from Kumasi, Ghana, West Africa. In all








C or below and trans-
ported in dry ice.
The first set of donors was tested in 1999 to 2000 with
an HBsAg enzyme immunoassay (EIA; Abbott/Murex,
Dartford, UK) that has a sensitivity of 0.2 ng per mL.
Seroreactive deferred donor samples were confirmed with
an alternative EIA (Biokit, Valencia, Spain) and tested for
alanine aminotransferase (ALT) level (upper normal level,
40 IU/L). Forty donors from the same set were selected for
having on two consecutive occasions, at least 1 month
apart, an ALT level above 60 IU per L (range, 60-865;
median, 185) as evidence of liver disease and entry criteria
in a randomized clinical trial for treatment with a local,
plant-derived drug.
There were 32 men and 8 women, ranging in age
between 17 and 54 years (median, 24 years). Viral load was






















 and were HBeAg-positive, whereas the other
18 samples were below that level and were anti-HBe–
positive.
HBsAg was semiquantified in the following way.
Plasma  samples  were  serially  diluted  by  a  factor  of 10
in saline, and each of the seven dilutions was tested with
the HBsAg screening EIA. Reactivity was expressed as
sample-to-cutoff ratio (S/CO). S/COs were then plotted
against dilution on a bilogarithmic scale, and the two to
four samples with a S/CO below maximum were used to
derive a best-fit curve that intersected the base line of S/
CO of 1. This intersection was considered as extinction
dilution and taken as reflecting the concentration of
HBsAg.
As shown in Fig. 1A, no correlation was found
between viral load that reflects the viral replication and
HBsAg endpoint dilution that reflects the level of synthesis
of surface protein. All but one sample gave a positive sig-
nal with the EIA when diluted 1:100,000 or higher. Seven
of eight samples containing less than 100 IU per mL HBV
DNA (approximately 500 copies) gave a positive signal
when diluted 1:1 mol per L. Conversely, the apparent level





 IU per mL was similar to samples with the lowest
DNA copy number.
A second group of donors was first tested before
donation in 2002 to 2003 with a rapid test (Determine
HBsAg, Abbott, Delkenheim, Germany) with a 1 ng per mL
limit of detection. Negative donations were then tested by
EIA (HBsAg Murex/Abbott) without dilution and found to
be reactive. All samples were negative for the presence of
anti-HBs. When tested by Q-PCR for the presence of HBV
DNA, 53 samples were positive. In 45 cases, S/CO was
between 1 and a maximum of 10. In that zone, S/CO was
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Results are expressed in IU per mL. One IU per mL 
corresponds to approximately 5 copies per mL. All donors had ALT levels of greater than 60 IU per L, and samples were tested before 




(B) Blood donations did not react with a HBsAg rapid test (sensitivity, 1 ng/mL) used before 
donation did react with an EIA (sensitivity, 0.2 ng/mL). A majority of samples had a sample to cutoff ratio below maximum and a viral 
load below 100 IU per mL.
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expected to reflect HBsAg concentration. Figure 1B shows
the absence of correlation between HBsAg S/CO and HBV
DNA load. Nearly all samples contained less than 1000 IU
per mL HBV DNA, and 33 (62%) contained less than
100 IU per mL or approximately 500 copies per mL. Five
samples (9.4%) were anti-HBc–negative.





 showing that, in chronic HBV infec-
tion, the apparent concentration of surface antigen in
plasma does not correlate with the level of circulating viral
DNA. This might reflect the considerable difference
between the release of viral structural proteins and the
formation of full virions released in the circulation. Non-
encapsidated viral DNA tends to be rapidly destroyed
whereas, in the absence of anti-HBs, surface antigen
produced by either infected cells or integrated viral
genome may remain in circulation for prolonged periods
of time.
The gap in apparent HBsAg concentration between
the first and second set of data is difficult to explain. Thir-
teen samples in the first set had a viral load below 1000 IU
per mL, similar to what was found in the second set. Yet,
S/CO below the maximum absorbance level was found




 in the first set and undi-
luted in the second, with the same EIA. Although the pop-
ulation of donors with liver disease tended to be older









 IU per mL also tended to be older (median,
23 years vs. 28 years), neither difference was significant. It
is possible that donors with liver disease have more inte-
grated viral DNA producing HBsAg but no virions. The
dual origin of HBsAg (viral replication and production
from integrated DNA) might explain the presence of rare









able HBsAg without detectable HBV DNA. In such cases,
a very low production of potentially infectious virus can-
not be excluded. Conversely, the presence of occult HBV
infection (HBV DNA–positive, HBsAg-negative) might not




 As a result, blood safety
might continue to benefit from sensitive detection meth-
ods of both HBsAg EIA and HBV DNA.
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Yield of hepatitis C virus nucleic acid testing 
among antibody-reactive or confirmed-
positive samples
 
In contrast to acute hepatitis B virus infections in adults,
of which only 1 to 3 percent become chronic, acute hepa-
titis C virus (HCV) infections progress to chronicity in a
high proportion of cases, with reported rates of persistent




 Spontaneous HCV clearance
has been correlated with age at infection, race-ethnicity,





 Rates of HCV viremia detected by nucleic acid
testing (NAT) have ranged from 74 to 86 percent in large





 HCV NAT rates, however, may become lower
with increased use of NAT and the introduction of more
sensitive third-generation antibody assays.
In a recent article on NAT yield in German blood




 reported HCV viremia rates
for 462 anti-HCV–positive donations confirmed by a
second-generation semiautomated HCV antibody assay
(Matrix, Abbott Laboratories, Delkenheim, Germany;
before summer 2001) and antibody-reactive results con-
firmed by an HCV line immunoassay (Inno-Lia HCV anti-
body III update, Innogenetics, Gent, Belgium; after
summer 2001). These seropositive samples had been tested
by HCV NAT in pools containing up to 96 donor samples,
and if RNA-negative, by single-sample NAT. Of 268 donor
samples from the German Red Cross Institute Frankfurt,
187 (69.8%) tested RNA-positive, whereas only 84 (43.3%)
of 194 samples from the Bavarian Red Cross tested positive
by NAT. The surprisingly low rate of viremia observed in
the HCV seropositive donors from the Bavarian Red Cross
(relative to other donor populations in Germany and else-
where) could not be explained by known correlates of clear-
ance, which led to this investigation.
 
LETTERS TO THE EDITOR
 




To confirm the RNA and antibody
status of blood donor samples that
had been classified as NAT-negative and
HCV-seropositive in the previously pub-
lished report, 110 of the original Bavar-
ian donor samples and 5 of the original
donor samples from Frankfurt were
reanalyzed by two independent labora-
tories (Blood Systems Research Insti-
tute, San Francisco, CA, in collaboration
with Chiron Corp., Emeryville, CA; and
the German Red Cross Institute Frank-
furt). The working plan and results from
both laboratories are summarized in
Fig. 1. All samples tested negative for
the presence of HCV RNA (TMA Procleix
Ultrio [Chiron Corp.] in San Francisco
and in-house single-sample polymerase
chain reaction [PCR] in Frankfurt), con-
firming the sensitivity of the original
NAT screening system. Antibody-
positive samples were confirmed by a
third-generation HCV recombinant
immunoblot assay (RIBA) (US) and by
Inno-Lia HCV antibody III update
(Germany). Whereas all five original
samples from Frankfurt were confirmed
HCV antibody–positive in both laboratories, only 9 of 51
Bavarian samples could be confirmed for the presence of
HCV antibody with RIBA and 16 of 43 samples could be
confirmed with Inno-Lia HCV antibody III update. Based
on these confirmed HCV antibody results, the recalcu-
lated rates of viremia by minipool and single-sample PCR
among the HCV antibody confirmed-positive samples
were 187 of 268 (69.8%) and 84 of 109 (77%) for the
Frankfurt and Bavarian Red Cross Centers, respectively.
Therefore, there was no significant difference between the





 0.19), in accordance with other results in the
literature.
Thus, the explanation for the low rate of reported
viremia among the Bavarian donors was the inclusion of
false-positive donor samples in the denominator of con-
firmed-positive donors, rather than the sensitivity of the
NAT screening assay or unique demographic or epidemi-
ologic factors. One explanation for these results could be
the use of the less specific Matrix assay instead of RIBA or
Inno-Lia HCV antibody III update in the initial study for
confirmation of HCV antibody–reactive samples. In each
institute (Bavarian Red Cross and German Red Cross Insti-
tute Frankfurt), 50 Inno-Lia HCV antibody III update–
positive donations were additionally analyzed by NAT
between 2001 and 2004. The Bavarian samples and the
Frankfurt samples were 62 and 70 percent NAT positive,
respectively. The recent data from both institutes is there-
fore in accordance with the literature and our retest results
and indicate no significant difference between rates of
HCV viremia among seropositive donors from either
region. It is not possible, retrospectively, to determine the
exact source of technical problems with the application of
the second-generation Matrix HCV test at the Bavarian
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Fig. 1. Repeat analysis of 115 samples that had been initially confirmed HCV antibody–
positive: 56 samples were analyzed in San Francisco by NAT TMA Procleix Ultrio (Chi-
ron Corp.), anti-HCV Ortho ECi, anti-HCV Ortho third-generation enzyme immunoas-
say, and HCV third-generation RIBA. Forty-eight samples were retested in Frankfurt 
using in-house single-donor PCR, anti-HCV AxSym (Abbott Laboratories), and HCV 
Inno-Lia HCV antibody III update (Innogenetics). neg = negative; pos = positive.
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Re: Toward an understanding of transfusion-
related acute lung injury: statement of a 
consensus panel
The recently published consensus statement on under-
standing transfusion-related acute lung injury (TRALI)1
contains several errors pertaining to the work of our group
(authors’ reference 21).2 Suspecting that the errors might
reflect an incorrect bibliographical citation, we searched
computerized databases, but cannot find an explanation.
Virtually all of the citations to our work in this consensus
statement are incorrect, as follows:
• “Rat lungs were ventilated, perfused . . . .” We did not
use rat but rabbit lungs.
• “. . . and subsequently monoclonal anti-HNA-
2a . . . was added to the perfusate . . . .” We did not use
monoclonal, but polyclonal, alloantibodies from a
blood donor, implicated in TRALI.
• (Same as above) The specificity of the antibody, added
to the perfusate, was anti-HNA-3a or in former termi-
nology anti-5b, not anti-HNA-2a.
• “The response was blunted when less than 30 percent
HNA-2a-positive neutrophils were used.” We did not
find such a threshold of 30 percent and did not men-
tion it.
• “The onset of these events was accelerated by the
addition of the neutrophil activator formyl-methio-
nyl-leucyl-phenylalanine.” We did not use this
activator.
• “Lung histology showed pulmonary edema and neu-
trophil accumulation.” We did not perform histology;
we just evaluated cell counts and microscopic
smears.
Erroneous citations in this widely read consensus
statement will, we are concerned, lead to misunderstand-
ings with regard to our past, present, and future research
in this field.3-8 They should be rectified.
Jürgen Neppert, MD
e-mail: juergen.neppert@web.de
Esther v. Witzleben-Schürholz, MD
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The above letter was sent to Kleinman et al.: Drs Davenport
and Kleinman offered the following reply.
We thank Neppert and v. Witzelben-Schürholz for their
comments about our incorrect citation of their work and
extend our sincere apologies to them and their colleagues.
The data in our report attributed to Seeger and colleagues
(our reference 21) should have been attributed to Bux. Bux
presented these data on their ex vivo rat lung model at the
consensus conference and have published these data in
abstract form.1
Although the data were not presented at this confer-
ence, Neppert and colleagues previously published
important pioneering work on an ex vivo model of trans-
fusion-related acute lung injury (TRALI).2 As pointed out
in their letter, this model used isolated rabbit lungs that
were perfused with human neutrophils, plasma contain-
ing anti-5b, and fresh rabbit plasma as a complement
source. Appropriate control experiments were also
conducted.
We would like to emphasize that apart from this
incorrect citation, the consensus statement as published
in TRANSFUSION accurately reflects the proceedings of
the conference and the consensus of the full panel.3
Robertson Davenport, MD
Steven Kleinman, MD
On behalf of the TRALI Conference Consensus Panel
e-mail: skleinman@shaw.ca
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Naturally occurring anti-Jka
We report a case of “naturally occurring” anti-Jka in a 7-
month-old boy with orchitis, epididymitis, and an Escher-
ichia coli urinary tract infection.
The boy was born via cesarean section after 38 weeks
of his mother’s first and uneventful pregnancy. She had
no history of transfusion. Physical examination was unre-
markable, except for a tender mass in the left scrotum,
which was consistent with orchitis or epididymitis by
color Doppler examination. The complete blood cell
count was normal. Culture of a midstream urine sample
grew E. coli, more than 105 colony-forming units per mm3.
His red blood cells (RBCs) typed as group O, D+. An anti-
body detection test was positive and anti-Jka was
identified by gel test using a low-ionic-strength saline
(LISS)-Coombs card (DiaMed AG, Cressier, Morat, Swit-
zerland). An antibody detect test was negative when
repeated using a NaCl-enzyme card (DiaMed AG, Cress-
ier). Anti-Jka activity was not reduced by dithiothreitol
treatment, suggesting that the antibody was mostly
immunoglobulin G (IgG). We did not perform a monocyte
monolayer or other in vitro assay to evaluate the potential
clinical significance of the antibody. The patient’s and his
mother’s RBCs typed as Jk(a–b+). Both had negative
results for direct antiglobulin tests and anti-nuclear anti-
body tests. The mother’s antibody detection test was
negative.
These serologic findings were unchanged on four
subsequent serum samples collected during an 8-day hos-
pitalization. An antibody detection test was negative when
repeated 6 months after discharge.
We are aware of only one other case report of natu-
rally occurring anti-Jka.1 In that report, anti-Jka was
detected by strong serologic reactivity in a solid-phase
RBC adherence (SPRCA) assay, but not by indirect anti-
globulin test tube method in LISS or polyethylene glycol
or with papain- or ficin-treated RBCs. In contrast, anti-Jka
in our patient had strong reactivity in the gel test, which
we consider to be less sensitive than SPRCA. We are able
to exclude primary alloimmunization because of mater-
nal-fetal hemorrhage, because the patient’s and his
mother’s RBC phenotypes were Jk(a–). Primary alloimmu-
nization via maternal-fetal hemorrhage could not be
excluded in the first report of naturally occurring anti-Jka,
because the mother’s RBCs were Jk(a+).1
Perhaps the most interesting finding in our study is
the E. coli genitourinary infection. Several studies have
described an association between blood group antigens
and microbial infections,2-5 although there appears to be
only one report associating infection and Kidd blood
group antigens.5 That report described transient auto-
anti-Jkb in a patient with a proteus urinary tract infection.
Typically, naturally occurring antibodies are immu-
noglobulin M and, uncommonly, IgG as in our patient.
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The basis for this phenomenon is not known. In the
absence of information concerning the clinical signifi-
cance of naturally occurring anti-Jka, in general, and for
our patient’s anti-Jka, specifically, we have recommended
that Jk(a–) RBCs be selected, if our patient requires a
future transfusion.
Although anti-Jka is detected rarely in the absence of
exposure allogeneic Jk(a+) RBCs, we suggest that anti-Jka
be added to future listings of blood group antibodies that
may be “naturally occurring.”
Hyung Hoi Kim, MD, PhD
e-mail: hhkim@pusan.ac.kr
Tae Sung Park, MD
Department of Laboratory Medicine
Wan Lee, MD
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